title: Hypofractionated radiation therapy for inoperable advanced stage non-small cell lung cancer.
abstract: OBJECTIVE
  Inoperable advanced stage lung cancer is usually treated by radiation therapy. Although a minority of patients may achieve prolonged survival with aggressive therapeutic approaches, most patients present with adverse prognostic factors that do not allow curative treatment. For these cases palliation of symptoms becomes the main treatment purpose, and short treatment schedules are commonly employed.
  
  
  METHODS
  Fifty-two inoperable patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with a hypofractionated schedule of radiotherapy. Initially all patients received 20 Gy in five fractions, and approximately one month after irradiation completion patients underwent clinical and radiological evaluation. Those that achieved a >50% reduction in tumor load and respiratory symptoms were submitted to a second similar short course of radiotherapy.
  
  
  RESULTS
  Thirty-three (63%) patients received only one course of radiotherapy. After the first evaluation, 19 patients (37%), all stage IIIB, fulfilled the criteria to receive a total dose of 40 Gy. Survival rates at one and two years were 33% and 0%, respectively, in the group of patients that received 20 Gy, and 52% and 21% respectively, in the group treated with 40 Gy. Two-year survival rates were 10% for stage IIIB and 0% for stage IV patients. Among the patients that were irradiated with a dose of 20 Gy, a subjective reduction of dyspnea and cough and remission of hemoptysis were observed in 97%, 82% and 80% cases, respectively. Complete remission of dyspnea and coughing was observed in 17 (89%) and 14 (74%) patients treated with two irradiation courses. Only mild toxicity was recorded.
  
  
  CONCLUSIONS
  Our treatment schedule achieved symptom control in the majority of patients. Early evaluation after 20 Gy allowed selection of responsive patients that could benefit from more prolonged treatment.
authors.affiliation: Istituto di Radiologia, Cattedra di Radioterapia, Università degli Studi La Sapienza, Rome, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Donato
authors.forename: A
authors.initials: A
authors.lastname: Zurlo
authors.forename: P
authors.initials: P
authors.lastname: Bonfili
authors.forename: M
authors.initials: M
authors.lastname: Petrongari
authors.forename: M
authors.initials: M
authors.lastname: Santarelli
authors.forename: A
authors.initials: A
authors.lastname: Costa
authors.forename: R M
authors.initials: RM
authors.lastname: Enrici
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D016019:Survival Analysis; D016896:Treatment Outcome